US$ 20.31
glp 1 drugs and lupus GLP-1 Medications: A New Hope for Patients Do SGLT2 and GLP-1 therapies
Description
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Upcoming general anesthesia
For patients with chronic kidney disease, heart failure, or established atherosclerotic cardiovascular disease, substituting a sodium-glucose cotransporter 2 (SGLT2) inhibitor may be preferred

Through the program, which runs through December 31, 2027, eligible Medicare beneficiaries can access certain GLP1 medications for $50 per month, offering more predictable and affordable pricing for patients who qualify

doi: 10.1186/s40795-019-0293-8
